ClinicaliQ Trial Snapshot
- Study to Evaluate INCB123667 Versus Investigator’s Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting • Phase III • Oncology • NCT07214779.
- What is being tested: INCB123667, a targeted therapy, is being compared against standard chemotherapy regimens in patients with platinum-resistant ovarian cancer specifically selected for cyclin E1 overexpression, a molecular biomarker associated with poor prognosis.
- Patient eligibility overview: The trial targets patients with platinum-resistant ovarian cancer (disease progression within 6 months of platinum-based therapy) who have confirmed cyclin E1 overexpression, representing a defined subset of this chemotherapy-refractory population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Eligibility Snapshot
- : * Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Have platinum-resistant disease. * Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum containing regimen. * Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum. * Archival FFPE tumor tissue block or slides from a specimen no older than 5 years must be available. If not available, participant must be willing to undergo a pretreatment tumor biopsy. * Received at least 1 and no more than 4 prior lines of systemic therapy following the initial diagnosis, after which single-agent chemotherapy is considered an appropriate next therapeutic option. * Should have received prior treatment with bevacizumab unless there was a contraindication for its use. * Should have received prior treatment with mirvetuximab soravtansine if the tumor is positive for FRα, unless there is an exception for its use on medical grounds. * Measurable disease per RECIST v1.1.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.